{
  "trial_id": "NCT00931879",
  "trial_group": "diabetes",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, diabetes duration, triglyceride levels, C-peptide levels, presence of diabetic retinopathy, presence of diabetic nephropathy, presence of non-diabetic neuropathy, history of macrovascular events, use of ACE inhibitors or ARBs, liver enzyme levels, presence of pedal edema, history of heart failure, concomitant medication use.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Qualifying triglyceride level (mg/dL)",
          "triglyceride levels"
        ],
        [
          "C-peptide (ng/mL)",
          "C-peptide levels"
        ],
        [
          "serum glutamate oxaloacetate transaminase(AST) (u/L)",
          "liver enzyme levels"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Race (NIH/OMB)",
        "Weight (lbs)",
        "BMI kg/m^2",
        "Total cholesterol (mg/dL)",
        "HDL cholesterol (mg/dL)",
        "LDL cholesterol (mg/dL)",
        "HbA1c (%)",
        "Fasting glucose (mg/dL)",
        "serum glutamate pyruvate transaminase (ALT) (u/L)",
        "Alkaline phosphatase (u/L)",
        "Insulin (uIU/mL)"
      ],
      "remaining_candidate_features": [
        "diabetes duration",
        "presence of diabetic retinopathy",
        "presence of diabetic nephropathy",
        "presence of non-diabetic neuropathy",
        "history of macrovascular events",
        "use of ACE inhibitors or ARBs",
        "presence of pedal edema",
        "history of heart failure",
        "concomitant medication use."
      ]
    },
    "processed-gen-response": "Age, sex, diabetes duration, triglyceride levels, C-peptide levels, presence of diabetic retinopathy, presence of diabetic nephropathy, presence of non-diabetic neuropathy, history of macrovascular events, use of ACE inhibitors or ARBs, liver enzyme levels, presence of pedal edema, history of heart failure, concomitant medication use."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Duration of Diabetes, Baseline Triglyceride Levels, Baseline HbA1c, Blood Pressure, BMI, Presence of Diabetic Neuropathy, Use of ACE-inhibiting agents or ARBs, Liver Function Tests,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Qualifying triglyceride level (mg/dL)",
          "Baseline Triglyceride Levels"
        ],
        [
          "HbA1c (%)",
          "Baseline HbA1c"
        ],
        [
          "BMI kg/m^2",
          "BMI"
        ],
        [
          "C-peptide (ng/mL)",
          "Presence of Diabetic Neuropathy"
        ],
        [
          "serum glutamate oxaloacetate transaminase(AST) (u/L)",
          "Liver Function Tests"
        ],
        [
          "serum glutamate pyruvate transaminase (ALT) (u/L)",
          "Liver Function Tests"
        ],
        [
          "Alkaline phosphatase (u/L)",
          "Liver Function Tests"
        ]
      ],
      "remaining_reference_features": [
        "Race (NIH/OMB)",
        "Weight (lbs)",
        "Total cholesterol (mg/dL)",
        "HDL cholesterol (mg/dL)",
        "LDL cholesterol (mg/dL)",
        "Fasting glucose (mg/dL)",
        "Insulin (uIU/mL)"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "Duration of Diabetes",
        "Blood Pressure",
        "Use of ACE-inhibiting agents or ARBs"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Duration of Diabetes, Baseline Triglyceride Levels, Baseline HbA1c, Blood Pressure, BMI, Presence of Diabetic Neuropathy, Use of ACE-inhibiting agents or ARBs, Liver Function Tests"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Diabetes Duration, Triglyceride Levels, HbA1c, Body Mass Index, Systolic Blood Pressure, Diastolic Blood Pressure, History of Diabetic Neuropathy, History of Diabetic Retinopathy, History of Diabetic Nephropathy.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Qualifying triglyceride level (mg/dL)",
          "Triglyceride Levels"
        ],
        [
          "HbA1c (%)",
          "HbA1c"
        ],
        [
          "BMI kg/m^2",
          "Body Mass Index"
        ]
      ],
      "remaining_reference_features": [
        "Race (NIH/OMB)",
        "Weight (lbs)",
        "Total cholesterol (mg/dL)",
        "HDL cholesterol (mg/dL)",
        "LDL cholesterol (mg/dL)",
        "Fasting glucose (mg/dL)",
        "serum glutamate oxaloacetate transaminase(AST) (u/L)",
        "serum glutamate pyruvate transaminase (ALT) (u/L)",
        "Alkaline phosphatase (u/L)",
        "C-peptide (ng/mL)",
        "Insulin (uIU/mL)"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "Diabetes Duration",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure",
        "History of Diabetic Neuropathy",
        "History of Diabetic Retinopathy",
        "History of Diabetic Nephropathy"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Diabetes Duration, Triglyceride Levels, HbA1c, Body Mass Index, Systolic Blood Pressure, Diastolic Blood Pressure, History of Diabetic Neuropathy, History of Diabetic Retinopathy, History of Diabetic Nephropathy."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, body mass index (BMI), duration of type 2 diabetes, triglyceride levels, C-peptide levels, presence of diabetic retinopathy, presence of diabetic nephropathy, presence of neuropathy, history of macrovascular events, use of ACE-inhibiting agents or angiotensin receptor blockade therapy (ARB), liver enzyme levels, presence of pedal edema, New York Heart Association Class, concomitant medications.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "BMI kg/m^2",
          "body mass index (BMI)"
        ],
        [
          "Qualifying triglyceride level (mg/dL)",
          "triglyceride levels"
        ],
        [
          "C-peptide (ng/mL)",
          "C-peptide levels"
        ],
        [
          "serum glutamate oxaloacetate transaminase(AST) (u/L)",
          "liver enzyme levels"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Race (NIH/OMB)",
        "Weight (lbs)",
        "Total cholesterol (mg/dL)",
        "HDL cholesterol (mg/dL)",
        "LDL cholesterol (mg/dL)",
        "HbA1c (%)",
        "Fasting glucose (mg/dL)",
        "serum glutamate pyruvate transaminase (ALT) (u/L)",
        "Alkaline phosphatase (u/L)",
        "Insulin (uIU/mL)"
      ],
      "remaining_candidate_features": [
        "duration of type 2 diabetes",
        "presence of diabetic retinopathy",
        "presence of diabetic nephropathy",
        "presence of neuropathy",
        "history of macrovascular events",
        "use of ACE-inhibiting agents or angiotensin receptor blockade therapy (ARB)",
        "presence of pedal edema",
        "New York Heart Association Class",
        "concomitant medications."
      ]
    },
    "processed-gen-response": "Age, sex, body mass index (BMI), duration of type 2 diabetes, triglyceride levels, C-peptide levels, presence of diabetic retinopathy, presence of diabetic nephropathy, presence of neuropathy, history of macrovascular events, use of ACE-inhibiting agents or angiotensin receptor blockade therapy (ARB), liver enzyme levels, presence of pedal edema, New York Heart Association Class, concomitant medications."
  }
}